SYGNIS AG

EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Announces Prolongation of Standby Equity Distribution Agreement

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
31.07.2012

Ad hoc-Release according to § 15 WpHG
SYGNIS Announces Prolongation of Standby Equity Distribution Agreement


Heidelberg,  July 31, 2012  -  SYGNIS   Pharma   AG   (Frankfurt:   LIOK;   ISIN
DE000A1E9B74; Prime Standard) has ahead of schedule  agreed  a  prolongation  of
the standby equity distribution agreement (SEDA) with YA Global Master  SPV  LTD
(YA Global) effective from  November  1,  2012  for  further  three  years  with
unchanged conditions. The agreement provides SYGNIS Pharma AG  with  the  option
to request YA Global, during the term of the agreement, to subscribe  for  newly
issued SYGNIS shares from the Company's authorized capital in tranches of up  to
EUR 500,000 each. The subscription price of the new shares will be  determined 
at 95% of the lowest volume-weighted average price of one of the five trading 
days following the date of the relevant draw down notice.

The total value of this equity  facility  aggregates  to  up  to  EUR 10 
million, provided that the aggregate number of shares  issued  to  YA  Global 
shall  not exceed  9,9%  of  SYGNIS  Pharma  AG's  share  capital.  YA  Global 
can  either accumulate these shares or place them in  the  market.  However,  YA
Global  is committed not to short sell or enter into any hedging  transactions 
related  to the particular company stock.

The prolongation is subject to the condition precedent that the  German  Federal
Financial Supervisory Authority (Bundesanstalt für
Finanzdienstleistungsaufsicht) grants an exemption from the obligations
pursuant to sec.35 of the German Takeover Act (Wertpapiererwerbs-  und
Übernahmegesetz)toGenetrix, A.B., and parties affiliated or acting in  concert
with Genetrix, A.B., regarding the proposed contribution of  X-Pol  into  SYGNIS
Pharma AG in particular to submit a  mandatory  tender  offer  to  the  existing
shareholders of  SYGNIS  Pharma  AG  in  connection  with  the  related  capital
increase of SYGNIS Pharma AG.

**** end of ad hoc ****
For further information please contact:


|SYGNIS Pharma AG                    |                                    |     
                              |                                    |
|Peter Willinger                     |                                    |     
                              |                                    |
|Tel: +49 6221 454 836               |                                    |     
                              |                                    |
|Email: peter.willinger@sygnis.de |                                    |     
                              |                                    |


### Disclaimer

This publication is intended for information only  and  constitutes  neither  an
offer to sell nor an invitation to buy securities. Some statements  included  in
this press release, relating neither  to  proven  financial  results  nor  other
historical data, should be viewed as forward-looking, i.e.  not  definite.  Such
statements are mainly predictions of future results,  trends,  plans  or  goals.
These statements should not be considered to be  total  guarantees  since  given
their  very  nature  they  are  subject  to  known   and   unknown   risks   and
imponderability and can be affected by other factors as a consequence  of  which
the actual results, plans and goals of SYGNIS  Pharma  AG  may  deviate  greatly
from the established  conclusions  or  implied  predictions  contained  in  such
statements. SYGNIS does  not  undertake  to  publicly  update  or  revise  these
statements in the light of new information or future results or  for  any  other
reason.
###


Further inquiry note:
Marc Risch
Telefon: +49 (6221) 454 - 737
E-Mail: Marc.Risch@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:     contact@sygnis.de
WWW:      http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: